Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events
Abstract
OBJECTIVE: To determine the relationship between the presence of antiphospholipid (aPL) antibodies, hydroxychloroquine use and the occurrence of thrombotic events in patients with systemic lupus erythematosus (SLE). METHODS: Four hundred and forty-two SLE patients from the LUMINA (Lupus in Minorities: Nature vs Nurture) cohort, a multiethnic (Hispanics from Texas, n = 99 and Puerto Rico, n = 36; African Americans, n = 172; and Caucasians, n = 135) cohort, were studied by generalized estimating equation (GEE) to determine the relationship between antiphospholipid (aPL) antibodies (measured as IgG and IgM aPL antibodies and/or the lupus anticoagulant) at enrolment or historically prior to enrolment, hydroxychloroquine use (ever) and the occurrence of thrombotic (central and/or peripheral, arterial and/or venous) events after adjusting for known and possible confounders [socioeconomic-demographic features, smoking, disease activity and damage, serum cholesterol levels, anti-oxidized low-density lipoprotein IgG and IgM antibodies, and high-sensitivity (hs) C-reactive protein]. Postanalysis correlation between aPL and anticardiolipin (aCL) assays was attempted by performing aCL assays on random samples of patients whose aPL status was known. RESULTS: A number of clinical variables were significant in the univariable analyses; however, in the multivariable GEE analyses, only smoking [odds ratio (OR) 2.777, 95% confidence interval (CI) 1.317-5.852] and disease activity as measured by the SLAM (Systemic Lupus Activity Measure) (OR 1.099; 95% CI 1.053-1.147) were significant. In particular, hydroxychloroquine use, which appeared to be protective against thrombotic events in the univariable analyses, was not retained in the multivariable analyses. aPL antibodies were not significant in either analysis. Few additional aPL-positive patients emerged from the validation study. CONCLUSIONS: Smoking and disease activity emerged as important determinants in the occurrence of thrombotic events in our patients. Comprehensive treatment strategies should be directed to both smoking cessation and control of disease activity in patients with SLE.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Prior retrospective and prospective studies have shown that hydroxychloroquine lowers the risk of arterial and venous thrombosis in systemic lupus erythematosus.
“Multiple retrospective and a few prospective studies (3–13) have found that hydroxychloroquine (HCQ) reduces the risk of arterial and venous thrombosis.”
From Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus (2021) · cites this paper as [4]
The Univariable analyses section reports that hydroxychloroquine use was protective against thrombotic events in the LUMINA cohort, which included arterial and venous events. But the Discussion says the association did not persist in the adjusted analysis. The paper also does not establish the claim's characterization of multiple retrospective and prospective studies finding a reduction. (LLM, conf=0.87)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519 · see citing works
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409 · see citing works
Cervera, R., Piette, J., Font, J., Khamashta, M. A., Shoenfeld, Y., Camps, M. T., Jacobsen, S., Lakos, G., Tincani, A., Kontopoulou‐Griva, I., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10187 · Cited by 2,156 · cited 1× · see citing works
“Contrary to what we had hypothesized based on the published literature [2, 9, 39–41], an association between aPL antibodies (each one individually or all taken together) was not found in either the univariable or the multivariable analyses even when a second assay was performed in a selected number of patient samples…”
ResultLove, P. E., & Santoro, S. A. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-9-682 · Cited by 1,095 · see citing works
Liang, M. H., Socher, S. A., Larson, M. G., & Schur, P. H. (1989) · Arthritis & Rheumatism · doi:10.1002/anr.1780320909 · Cited by 787 · see citing works
Gladman, D. D., Urowitz, M. B., Goldsmith, C. H., Fortin, P., Ginzler, E., Gordon, C., Hanly, J. G., Isenberg, D. A., Kalunian, K., Nived, O., et al. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400506 · Cited by 759 · see citing works
Risk Factors for Cardiovascular Disease in Systemic Lupus Erythematosus
Svenungsson, E., Jensen‐Urstad, K., Heimbürger, M., Silveira, A. M. V., Hamsten, A., Fairé, U. D., Witztum, J. L., & Frostegård, J. (2001) · Circulation · doi:10.1161/hc4101.097518 · Cited by 500 · see citing works
Doria, A., Shoenfeld, Y., Wu, R., Gambari, P. F., Puato, M., Ghirardello, A., Gilburd, B., Corbanese, S., Patnaik, M., Zampieri, S., et al. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.11.1071 · Cited by 403 · see citing works
Toloza, S., Uribe, A. G., McGwin, G., Alarcón, G. S., Fessler, B. J., Bastian, H. M., Vilá, L. M., Wu, R., Shoenfeld, Y., Roseman, J. M., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20622 · Cited by 319 · see citing works
Self-citationPaleolog, E. M., Young, S., Stark, A. C., McCloskey, R. V., Feldmann, M., & Maini, R. N. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199807)41:7 · Cited by 318 · see citing works
Self-citationAlarcón, G. S., Friedman, A., Straaton, K. V., Moulds, J. M., LISSE, J. R., Bastian, H. M., McGwin, G., Bartolucci, A. A., Roseman, J. M., & Reveille, J. D. (1999) · Lupus · doi:10.1191/096120399678847704 · Cited by 309 · see citing works
Self-citationBillah, M. M., Lapetina, E. G., & Cuatrecasas, P. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70453-0 · Cited by 287 · see citing works
Wahl, D., Guillemin, F., de Maistre, E., Perret, C., Lecompte, T., & Thibaut, G. (1997) · Lupus · doi:10.1177/096120339700600510 · Cited by 284 · cited 1× · see citing works
“with arterial events [2, 40], which may in part explain our negative findings; in fact, in separate analyses, LAC was found to be associated with venous thrombotic events [42].”
ResultHydroxychloroquine Reverses Thrombogenic Properties of Antiphospholipid Antibodies in Mice
Edwards, M. H., Pierangeli, S., Liu, X., Barker, J. H., Anderson, G., & Harris, E. N. (1997) · Circulation · doi:10.1161/01.cir.96.12.4380 · Cited by 250 · see citing works
The Frequency of Lupus Anticoagulant in Systemic Lupus Erythematosus
Petri, M., RHEINSCHMIDT, M., WHITING-O'KEEFE, Q., HELLMANN, D., & CORASH, L. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-4-524 · Cited by 232 · see citing works
Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients
Shah, N. M., Khamashta, M. A., Atsumi, T., & Hughes, G. R. (1998) · Lupus · doi:10.1191/096120398678919624 · Cited by 204 · see citing works
Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment
Jewell, M. L., & McCauliffe, D. P. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.103635 · Cited by 198 · see citing works
(2002) · PubMed · Cited by 191 · see citing works
Bessant, R. (2004) · British journal of rheumatology · doi:10.1093/rheumatology/keh213 · Cited by 182 · see citing works
Goldman, F. D., Gilman, A. L., Hollenback, C., Kato, R. M., Premack, B. A., & Rawlings, D. J. (2000) · Blood · doi:10.1182/blood.v95.11.3460 · Cited by 178 · see citing works
Alén, J. C., Toloza, S., Fernández, M., Bastian, H. M., Fessler, B. J., Roseman, J. M., McGwin, G., Vilá, L. M., Reveille, J. D., Alarcón, G. S., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21149 · Cited by 147 · see citing works
Self-citationSmoking interferes with efficacy of antimalarial therapy in cutaneous lupus.
Rahman, P., Gladman, D. D., & Urowitz, M. B. (1998) · PubMed · Cited by 145 · see citing works
A Hexagonal (II) Phase Phospholipid Neutralization Assay for Lupus Anticoagulant Identification
Triplett, D. A., Barna, L. K., & Unger, G. A. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649671 · Cited by 132 · see citing works
Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?
Wallace, D. J. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780301219 · Cited by 124 · see citing works
Cigarette smoking and disease activity in systemic lupus erythematosus.
Ghaussy, N. O., Sibbitt, W. L., Bankhurst, A. D., & Qualls, C. (2003) · PubMed · Cited by 120 · see citing works
Wallace, D. J., Linker‐Israeli, M., METZGER, A. L., & Stecher, V. J. (1993) · Lupus · doi:10.1177/0961203393002001041 · Cited by 111 · see citing works
Mechanism of Action of Antimalarial Drugs: Inhibition of Antigen Processing and Presentation
Fox, R. I., & Kang, H. (1993) · Lupus · doi:10.1177/0961203393002001031 · Cited by 104 · see citing works
On the inhibitory effect of chloroquine on blood platelet aggregation
Jančinová, V., Nosál, R., & Petríková, M. (1994) · Thrombosis Research · doi:10.1016/0049-3848(94)90270-4 · Cited by 85 · see citing works
Toloza, S., Roseman, J. M., Alarcón, G. S., McGwin, G., Uribe, A. G., Fessler, B. J., Bastian, H. M., Vilá, L. M., & Reveille, J. D. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20578 · Cited by 70 · see citing works
Self-citationAntiphospholipid Antibodies: Proposed Mechanisms of Action
Triplett, D. A. (1992) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.1992.tb00794.x · Cited by 56 · see citing works
Liang, M. H., Fortin, P. R., Isenberg, D. A., & Snaith, L. (1991) · Rheumatology International · doi:10.1007/bf00304502 · Cited by 40 · see citing works
McCrea, J. B., Robinson, P. J., & Gerrard, J. M. (1985) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(85)90202-8 · Cited by 38 · see citing works
Ieko, M., Sawada, K., Koike, T., Notoya, A., Mukai, M., Kohno, M., Wada, N., Itoh, T., & Yoshioka, N. (1999) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2007-994958 · Cited by 33 · see citing works
Gallus, A. S., & Hirsh, J. (1976) · Drugs · doi:10.2165/00003495-197612010-00002 · Cited by 29 · see citing works
Hoffman, M., Monroe, D. M., & Roubey, R. A. S. (2000) · Immunologic Research · doi:10.1385/ir:22:2-3:191 · Cited by 22 · see citing works
Gallus, A. S., & Hirsh, J. (1976) · Drugs · doi:10.2165/00003495-197612020-00002 · Cited by 19 · see citing works
Is the Antithrombotic Activity of “Antiplatelet” Drugs Based on Protection of Endothelium?
Hladovec, J. (1979) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646836 · Cited by 16 · see citing works
[Antiphospholipid antibodies: clinical significance and biological diagnosis].
Arnoux, D., Boutière, B., & Sanmarco, M. (2000) · PubMed · Cited by 14 · see citing works
Turpie, A. G. G. (1982) · PubMed · Cited by 2 · see citing works
Jp, R., Morel, S., Migaud-Fressart, M., & Martinoli, J. L. (1992) · Thrombosis Research · doi:10.1016/0049-3848(92)90746-w · Cited by 1 · see citing works
Komuro (2001) · doi:10.1002/1529-0131(200112)44:12
Self-citation
Flagged first, then by citations
1 of the 42 references couldn’t be matched to a known paper.
Research works printed but not linked: 6
- Alarco´n GS, Roseman J, Bartolucci AA et al. Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. Arthritis Rheum 1998;41:1173-80.
- Reveille JD, Moulds JM, Ahn C et al. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 1998;41:1161-72.
- Roisin J-P, Contant G, Martinoli J-L. Detection of lupus-like anticoagulants (LA). Use of hexagonal phosphatidylethanolamine and of an APTT reagent sensitive to LA. Thromb Haemost 1991; 65:2023.
- Alarco´n GS, McGwin G Jr, Bartolucci AA et al. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 2001;44:2797-806.
- Fessler BJ, McGwin G Jr, Roseman JM et al. Hydroxychloroquine (HCQ) usage is associated with decreased renal and cardiovascular damage in patients with systemic lupus erythematosus (SLE). Arthritis Rheum 2001;44:S201.
- Calvo-Ale´n J, Toloza SM, Ferna´ndez M et al. Smoking, hyper- cholesterolemia and glucocorticoid use are major risk factors for venous thrombosis in systemic lupus erythematosus. Arthritis Rheum 2004;50:S595.
Cited by
Sorted by citations
Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., & Khamashta, M. A. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101766 · Cited by 978 · see citing works
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
van Vollenhoven, R., Mosca, M., Bertsias, G. K., Isenberg, D. A., Kuhn, A., Lerstrøm, K., Aringer, M., Bootsma, H., Boumpas, D., Bruce, I. N., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205139 · Cited by 750 · see citing works
Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
Ruiz-Irastorza, G., Egurbide, M.-V., Pijoan, J.-I., Garmendia, M., Villar, I., Martinez-Berriotxoa, A., Erdozain, J.-G., & Aguirre, C. (2006) · Lupus · doi:10.1177/0961203306071872 · Cited by 411 · see citing works
Mosca, M., Tani, C., Aringer, M., Bombardieri, S., Boumpas, D., Brey, R. L., Cervera, R., Doria, A., Jayne, D. R. W., Khamashta, M. A., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.117200 · Cited by 377 · see citing works
Erkan, D., Aguiar, C. L., ANDRADE, D. C. O. D., Cohen, H., Cuadrado, M. J., Danowski, A., Levy, R. A., Ortel, T. L., Rahman, A., Salmon, J. E., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.053 · Cited by 317 · see citing works
Jung, H., Bobba, R., Su, J., Shariati‐Sarabi, Z., Gladman, D. D., Urowitz, M., Lou, W., & Fortin, P. R. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27289 · Cited by 291 · see citing works
Kaiser, R., Cleveland, C. M., & Criswell, L. A. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.093013 · Cited by 244 · see citing works
Smoke and autoimmunity: The fire behind the disease
Perricone, C., Versini, M., Ben-Ami, D., Gertel, S., Watad, ., Segel, M., Ceccarelli, F., Conti, F., Cantarini, L., Bogdanos, D. P., et al. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.01.001 · Cited by 242 · see citing works
Cigarette smoking and autoimmune disease: what can we learn from epidemiology?
Costenbader, K. H., & Karlson, E. W. (2006) · Lupus · doi:10.1177/0961203306069344 · Cited by 237 · see citing works
New insights into mechanisms of therapeutic effects of antimalarial agents in SLE
Wallace, D. J., Gudsoorkar, V. S., Weisman, M. H., & Venuturupalli, S. R. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.106 · Cited by 217 · see citing works
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge
Dima, A., Jurcuț, C., Chasset, F., Felten, R., & Arnaud, L. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211073001 · Cited by 228 · see citing works
Hydroxychloroquine: A multifaceted treatment in lupus
Costedoat-Chalumeau, N., Dunogué, B., Morel, N., Guern, V. L., & Guettrot-Imbert, G. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.03.007 · Cited by 195 · see citing works
Willis, R., Seif, A. M., McGwin, G., Martinez-Martinez, L.-A., González, E., Dang, N. N. A., Papalardo, E., LIU, J., Vilá, L., Reveille, J., et al. (2012) · Lupus · doi:10.1177/0961203312437270 · Cited by 189 · see citing works
Self-citationTobacco smoking and autoimmune rheumatic diseases
Harel, M., Sherer, Y., & Shoenfeld, Y. (2007) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0655 · Cited by 162 · see citing works
Quirós-Roldán, E., Biasiotto, G., Magro, P., & Zanella, I. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104904 · Cited by 153 · see citing works
The diagnosis and management of the haematologic manifestations of lupus
Velo-García, A., Castro, S. G., & Isenberg, D. A. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.07.001 · Cited by 161 · see citing works
Alén, J. C., Toloza, S., Fernández, M., Bastian, H. M., Fessler, B. J., Roseman, J. M., McGwin, G., Vilá, L. M., Reveille, J. D., Alarcón, G. S., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21149 · Cited by 147 · see citing works
Self-citationMultifaceted effects of hydroxychloroquine in human disease
Olsen, N. J., Schleich, M. A., & Karp, D. R. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2013.01.001 · Cited by 146 · see citing works
Cohen, H., Cuadrado, M. J., Erkan, D., Duarte‐García, A., Isenberg, D. A., Knight, J. S., Ortel, T. L., Rahman, A., Salmon, J. E., Tektonidou, M. G., et al. (2020) · Lupus · doi:10.1177/0961203320950461 · Cited by 165 · see citing works
The non-haemostatic role of platelets in systemic lupus erythematosus
Linge, P., Fortin, P. R., Lood, C., Bengtsson, A. A., & Boilard, É. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2018.38 · Cited by 125 · see citing works
Nuri, E., Taraborelli, M., Andreoli, L., Tonello, M., Gerosa, M., Calligaro, A., Argolini, L. M., Kumar, R., Pengo, V., Meroni, P. L., et al. (2017) · Immunologic Research · doi:10.1007/s12026-016-8812-z · Cited by 124 · see citing works
Alijotas‐Reig, J., Esteve‐Valverde, E., Anunciación-Llunell, A., Marques-Soares, J. R., Pardos‐Gea, J., & Miró‐Mur, F. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030675 · Cited by 127 · see citing works
Kostopoulou, M., Nikolopoulos, D., Parodis, I., & Bertsias, G. K. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161118666191227101636 · Cited by 114 · see citing works
Fasano, S., Pierro, L., Pantano, I., Iudici, M., & Valentini, G. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.161351 · Cited by 111 · see citing works
Koh, J. H., Ko, H. S., Kwok, S.-K., Ju, J. H., & Park, S.-H. (2014) · Lupus · doi:10.1177/0961203314555352 · Cited by 106 · see citing works
Haque, S., Gordon, C., Isenberg, D. A., Rahman, A., Lanyon, P., Bell, A. L., Emery, P., McHugh, N. J., Teh, L., Scott, D. G. I., et al. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090306 · Cited by 96 · see citing works
Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects
Tang, C., Godfrey, T., Stawell, R. J., & Nikpour, M. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2012.02886.x · Cited by 93 · see citing works
Cardiovascular Involvement in Autoimmune Diseases
Amaya‐Amaya, J., Montoya-Sánchez, L., & Rojas‐Villarraga, A. (2014) · BioMed Research International · doi:10.1155/2014/367359 · Cited by 92 · see citing works
Pierangeli, S. S., Chen, P. P., & González, E. B. (2006) · Current Opinion in Internal Medicine · doi:10.1097/01.moh.0000239710.47921.d2 · Cited by 87 · see citing works
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients
Hereng, T., Lambert, M., HACHULLA, E., Samor, M., Dubucquoi, S., Caron, C., Launay, D., Morell‐Dubois, S., Queyrel, V., & Hatron, P. (2007) · Lupus · doi:10.1177/0961203307084724 · Cited by 84 · see citing works
Wieczorek, M., Gwinnutt, J. M., Ransay-Colle, M., Balanescu, A. R., Bischoff-Ferrari, H. A., Boonen, A. E. R. C. H., Cavalli, G., de Souza, S., de Thurah, A. L., Dorner, T. E., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2021-002170 · Cited by 79 · see citing works
Thrombosis in Systemic Lupus Erythematosus and Other Autoimmune Diseases of Recent Onset
Romero‐Díaz, J., GARCÍA-SOSA, I., & Sánchez‐Guerrero, J. (2008) · The Journal of Rheumatology · doi:10.3899/jrheum.071244 · Cited by 78 · see citing works
Hydroxychloroquine: the cornerstone of lupus therapy
Ruiz‐Irastorza, G., & Khamashta, M. A. (2008) · Lupus · doi:10.1177/0961203307086643 · Cited by 76 · see citing works
Pego‐Reigosa, J. M., Cobo‐Ibáñez, T., Calvo‐Alén, J., Loza‐Santamaría, E., Rahman, A., Muñoz‐Fernández, S., & Rúa‐Figueroa, Í. (2013) · Arthritis Care & Research · doi:10.1002/acr.22035 · Cited by 74 · see citing works
New approaches for managing antiphospholipid syndrome
Erkan, D., & Lockshin, M. D. (2009) · Nature Reviews Rheumatology · doi:10.1038/ncprheum1017 · Cited by 71 · see citing works
Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis
Teixeira, V. S., & Tam, L. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2017.00262 · Cited by 71 · see citing works
Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?
Barbhaiya, M., & Erkan, D. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-010-0149-3 · Cited by 69 · see citing works
Petri, M., Konig, M. F., Li, J., & Goldman, D. W. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41621 · Cited by 65 · see citing works
Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus
Gustafsson, J. T., & Svenungsson, E. (2013) · Autoimmunity · doi:10.3109/08916934.2013.856005 · Cited by 59 · see citing works
Cigarette smoking, alcohol consumption and risk of systemic lupus erythematosus
Takvorian, S. U., Merola, J. F., & Costenbader, K. H. (2014) · Lupus · doi:10.1177/0961203313501400 · Cited by 58 · see citing works
Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?
Pierangeli, S., & Erkan, D. (2010) · Lupus · doi:10.1177/0961203310361489 · Cited by 56 · see citing works
Sciascia, S., Cuadrado, M. J., Sanna, G., Murru, V., Roccatello, D., Khamashta, M. A., & Bertolaccini, M. L. (2014) · Arthritis Care & Research · doi:10.1002/acr.22388 · Cited by 55 · see citing works
Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus
Becker-Merok, A., & Nossent, J. C. (2009) · Lupus · doi:10.1177/0961203308099233 · Cited by 54 · see citing works
Cigarette smoking and the risk of systemic lupus erythematosus and rheumatoid arthritis
Majka, D. S., & Holers, V. M. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.046052 · Cited by 54 · see citing works
Vikerfors, A., Johansson, A.-B., Gustafsson, J. T., Jonsen, A., Leonard, D., Zickert, A., Nordmark, G., Sturfelt, G., Bengtsson, A., Ronnblom, L., et al. (2013) · Rheumatology · doi:10.1093/rheumatology/kes252 · Cited by 51 · see citing works
Fasano, S., Margiotta, D. P. E., Navarini, L., Pierro, L., Pantano, I., Riccardi, A., Afeltra, A., & Valentini, G. (2017) · Lupus · doi:10.1177/0961203317722847 · Cited by 47 · see citing works
Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII)
Burgos, P. I., McGwin, G., Reveille, J. D., Vilá, L. M., & Alarcón, G. S. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq140 · Cited by 41 · see citing works
Self-citationGalarza-Maldonado, C. M., Kourilovitch, M., Molineros, J. E., Cardiel, M. H., Zurita, L., Soroka, N. F., Yagur, V., Doukh, N., & Cervera, R. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.08.012 · Cited by 39 · see citing works
Hsu, C.-Y., Lin, Y.-S., Su, Y.-J., Lin, H.-F., Lin, M.-S., Syu, Y.-J., Cheng, T.-T., Yu, S.-F., Chen, J.-F., & Chen, T.-H. (2017) · Rheumatology · doi:10.1093/rheumatology/kex357 · Cited by 38 · see citing works
Results of a specific smoking cessation program for patients with arthritis in a rheumatology clinic
Naranjo, A., Bilbao, A., Erausquin, C., Ojeda, S., Francisco, F., Rúa‐Figueroa, Í., & Rodríguez‐Lozano, C. (2013) · Rheumatology International · doi:10.1007/s00296-013-2851-8 · Cited by 38 · see citing works
Antipalúdicos en dermatología: mecanismo de acción, indicaciones y efectos secundarios
Rodríguez-Caruncho, C., & Bielsa, I. (2012) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2012.10.005 · Cited by 37 · see citing works
Watanabe, T., Oku, K., Amengual, O., Hisada, R., Ohmura, K., Nakagawa, I., Shida, H., Bohgaki, T., Horita, T., Yasuda, S., et al. (2017) · Lupus · doi:10.1177/0961203317716787 · Cited by 37 · see citing works
Thrombosis in systemic lupus erythematosus: risk and protection
Burgos, P. I., & Alarcón, G. S. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.137 · Cited by 34 · see citing works
Amaya‐Amaya, J., Sarmiento-Monroy, J. C., Caro‐Moreno, J., Molano‐González, N., Mantilla, R. D., Rojas‐Villarraga, A., & Anaya, J. (2013) · Autoimmune Diseases · doi:10.1155/2013/794383 · Cited by 35 · see citing works
Fernandez‐Ruiz, R., Bornkamp, N., Kim, M., Askanase, A., Zezon, A., Tseng, C.-E., Belmont, M. H., Saxena, A., Salmon, J. E., Lockshin, M. D., et al. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02282-0 · Cited by 33 · see citing works
Wang, T., & Lim, W. (2016) · Hematology · doi:10.1182/asheducation-2016.1.714 · Cited by 30 · see citing works
Juvenile polyautoimmunity in a rheumatology setting
Malagón, C., Gomez, M. D. P., Mosquera, C., Vargas, C., González, T., Arango, C., Martin, L., Perez, P., Amaya-Uribe, L., Molano‐González, N., et al. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.11.006 · Cited by 32 · see citing works
Cabrera-Marante, Ó., de Frías, E. R., Serrano, M., Lozano, F., Naranjo, L., Gil‐Etayo, F. J., Paz‐Artal, E., Pleguezuelo, D. E., & Serrano, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238972 · Cited by 32 · see citing works
D’Cruz, D. P., & Khamashta, M. A. (2009) · Springer eBooks · doi:10.1007/978-1-84800-934-9_16 · Cited by 31 · see citing works
Antimalarials in Dermatology: Mechanism of Action, Indications, and Side Effects
Rodríguez-Caruncho, C., & Bielsa, I. (2014) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2012.10.021 · Cited by 29 · see citing works
Genetic Risk Factors for Thrombosis in Systemic Lupus Erythematosus
Kaiser, R., Li, Y., Chang, M., Catanese, J. J., Begovich, A. B., Brown, E. E., Edberg, J. C., McGwin, G., Alarcón, G. S., Ramsey‐Goldman, R., et al. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.111451 · Cited by 28 · see citing works
Self-citationLife factors acting on systemic lupus erythematosus
Chen, J., Liao, S., Pang, W., Guo, F., Yang, L., Liu, J., & Pan, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.986239 · Cited by 27 · see citing works
Xu, D., You, X., Wang, Z., Zeng, Q., Xu, J., Jiang, L., Gong, L., Wu, F., Gu, J., Yi, T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134451 · Cited by 26 · see citing works
Factors associated with thrombosis in pediatric patients with systemic lupus erythematosus
Driest, K. D., Sturm, M., O’Brien, S. H., Spencer, C. H., Stanek, J. R., Ardoin, S. P., & for the CARRA Registry Investigators (2016) · Lupus · doi:10.1177/0961203316638164 · Cited by 26 · see citing works
Cornwell, M., Luttrell-Williams, E. S., Golpanian, M., Bannoudi, H. E., Myndzar, K., Izmirly, P., Belmont, M. H., Katz, S. D., Smilowitz, N. R., Engel, A., et al. (2021) · Lupus Science & Medicine · doi:10.1136/lupus-2021-000475 · Cited by 25 · see citing works
What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome?
Arachchillage, D. J., & Laffan, M. (2020) · British Journal of Haematology · doi:10.1111/bjh.16431 · Cited by 23 · see citing works
Lessons from LUMINA: a multiethnic US cohort
Alarcón, G. S. (2008) · Lupus · doi:10.1177/0961203308094359 · Cited by 24 · see citing works
Targeted therapy in antiphospholipid syndrome
Sciascia, S., Khamashta, M. A., & D’Cruz, D. P. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000051 · Cited by 23 · see citing works
Chighizola, C. B., Pregnolato, F., ANDRADE, D. C. O. D., Tektonidou, M. G., Pengo, V., Ruiz‐Irastorza, G., Belmont, M. H., Gerosa, M., Fortin, P. R., Branch, D. W., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42459 · Cited by 22 · see citing works
Tratamiento del lupus eritematoso sistémico: mitos, certezas y dudas
Ruiz‐Irastorza, G., Danza, Ã., & Khamashta, M. A. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.02.014 · Cited by 21 · see citing works
Lupus Registries: Evolution and Challenges
Lu, L., Wallace, D. J., Navarra, S., & Weisman, M. H. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.08.009 · Cited by 21 · see citing works
Choe, J., Lee, S., Kwak, S. G., & Kim, S. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e139 · Cited by 19 · see citing works
Farina, N., Webster, J., Luo, W., Garelick, D., Pinto, S. M., Isenberg, D. A., & Rahman, A. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152226 · Cited by 19 · see citing works
Venous thromboembolic disease in systemic autoimmune diseases: An association to keep in mind
Silvariño, R., Danza, Ã., Mérola, V., Bérez, A., Méndez, E., Espinosa, G., & Cervera, R. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.05.002 · Cited by 18 · see citing works
Molina, M. J., Mayor, Á. M., Franco, A. E., Morell, C., López, M. A., & Vilá, L. M. (2008) · PubMed · Cited by 14 · see citing works
Protective effects of antimalarials in Chinese patients with systemic lupus erythematosus
Wang, F., Zhang, W., Wang, S., Pan, W., Liu, L., Wu, M., Ding, F., Hu, H., Ding, X., Hua, W., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213819 · Cited by 14 · see citing works
Deciphering the clinical significance of longitudinal antiphospholipid antibody titers
Chighizola, C. B., Willis, R., Maioli, G., Sciascia, S., Andréoli, L., Amengual, O., Radin, M., Gerosa, M., Atsumi, T., de Jesús, G. R., et al. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103510 · Cited by 15 · see citing works
Predictors of avascular necrosis of the hip in Emiratis patients with systemic lupus erythematosus.
Saleh, J. A., Sayed, M. E., Salah, N., Harb, D. K., Khan, N., & Mohammed, N. (2010) · PubMed · Cited by 13 · see citing works
Aljohani, R., Gladman, D. D., Su, J., & Urowitz, M. B. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3713-7 · Cited by 11 · see citing works
Current management of antiphospholipid syndrome-related thrombosis
Puente, D., Pombo, G., & Forastiero, R. R. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.112 · Cited by 11 · see citing works
Wysokinska, E. M., & Ortel, T. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00020-0 · Cited by 11 · see citing works
Sakai, R., Honda, S., Tanaka, E., Majima, M., Konda, N., Takada, H., & Harigai, M. (2020) · Lupus · doi:10.1177/0961203320952853 · Cited by 10 · see citing works
Aviña-Zubieta, J. A., Daftarian, N., & Esdaile, J. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93232-5.00062-9 · Cited by 10 · see citing works
Fischer-Betz, R., & Schneider, M. (2008) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-008-0412-4 · Cited by 10 · see citing works
Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?
Devaux, C. A., Camoin‐Jau, L., Mège, J., & Raoult, D. (2021) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2020.12.010 · Cited by 9 · see citing works
Does hydroxychloroquine improve patient reported outcomes in patients with lupus?
Jolly, M., Sehgal, V., Arora, S. K., Azizoddin, D. R., Pinto, B., Sharma, A., Devilliers, H., Inoue, M., Toloza, S., Bertoli, A. M., et al. (2021) · Lupus · doi:10.1177/09612033211033983 · Cited by 6 · see citing works
The effect of hydroxychloroquine on platelet activation in model experiments
Schreiber, K. I., Sciascia, S., Wehrmann, F., Weiß, C., Leipe, J., Krämer, B. K., & Stach, K. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02325-y · Cited by 7 · see citing works
Shobha, V., Rajasekhar, L., Manuel, S., Nayana, V., Kavadichanda, C. G., Kounassegarane, D., Mathew, A. J., Gupta, R., Rathi, M., Ghosh, P., et al. (2023) · Rheumatology International · doi:10.1007/s00296-023-05511-2 · Cited by 6 · see citing works
Top 10 Clinical Research Developments in Antiphospholipid Syndrome
Barbhaiya, M., & Erkan, D. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-013-0367-6 · Cited by 6 · see citing works
Shin, S. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s146119 · Cited by 6 · see citing works
D’Cruz, D. P., Knight, J. S., Sammaritano, L. R., Salmon, J. E., Cervera, R., & Khamashta, M. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-23488-0_14 · Cited by 6 · see citing works
Aviña-Zubieta, J. A., & Esdaile, J. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1893-5.00049-2 · Cited by 4 · see citing works
Antiphospholipid syndrome and other lupus-related movement disorders
Plowman, E. K., & Okun, M. S. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52014-2.00016-1 · Cited by 4 · see citing works
Jeune, S. L., Pistorius, M.-A., Planchon, B., & Pottier, P. (2008) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2008.01.023 · Cited by 4 · see citing works
Nonanticoagulant Strategies for Venous Thromboembolism Prophylaxis
Gurumurthy, G., & Thachil, J. V. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2712-3534 · Cited by 3 · see citing works
Costedoat-Chalumeau, N., Leroux, G., Pietté, J. C., & Amoura, Z. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-374994-9.10057-9 · Cited by 3 · see citing works
Impact of Sex on Infection Risk in Patients with Systemic Lupus Erythematosus
Borrelli, R., Nicola, S., Corradi, F., Badiu, I., Sardo, L. L., Rashidy, N., Quinternetto, A., Mazzola, M., Meli, F., Saracco, E., et al. (2025) · Bioengineering · doi:10.3390/bioengineering12010059 · Cited by 2 · see citing works
Management of the antiphospholipid syndrome: new approaches
Seif, A. M., Hwang, Y. G., & Pierangeli, S. S. (2009) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.09.43 · Cited by 2 · see citing works
A new role for antimalarials in systemic lupus erythematosus treatment
Ayensa, J.-L., Khamashta, M. A., & Ruiz‐Irastorza, G. (2010) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.10.25 · Cited by 2 · see citing works
Williams, E. M., Crespo, C. J., & Dorn, J. P. (2009) · Digital Scholarship - UNLV (University of Nevada Reno) · Cited by 2 · see citing works
- Authors
- Ho, K. T., Ahn, C. W., Alarcón, G. S., Baethge, B. A., Tan, F. K., Roseman, J., Bastian, H. M., Fessler, B. J., McGwin, G., Vilá, L. M., Calvo-Alén, J., & Reveille, J. D.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- The University of Texas Medical Branch at Galveston (US)
- University of Alabama at Birmingham (US)
- Corresponding author
- Ho, K. T.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-19
- Volume
- 44
- Issue
- 10
- Pages
- 1303-1307
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2165897466
- Cited by
- 128
- References
- 42
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 5 · 2020: 10 · 2019: 5 · 2018: 3 · 2017: 6 · 2016: 7 · 2015: 1 · 2014: 11 · 2013: 11 · 2012: 13
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lara D. Veeken (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR042503)
- National Center for Research Resources (P20RR011126, M01RR000032, M01RR002558, M01RR000073)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vasculitis and related conditions
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- systemic lupus erythematosus, thrombotic complications, antiphospholipid antibodies, hydroxychloroquine, smoking, disease activity, lupus anticoagulant, anticardiolipin antibodies, cardiovascular risk factors, multi-ethnic cohort, Hispanic patients, African American patients, smoking cessation, oxidized LDL antibodies
- MeSH terms
- Epidemiologic Methods, Female, Humans, Hydroxychloroquine, Lupus Erythematosus, Systemic, Male, Severity of Illness Index, Smoking, Thrombosis, Antibodies, Antiphospholipid, Antirheumatic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
